TY - JOUR
T1 - Dietary supplement s-adenosyl-l-methionine (AdoMet) effects on plasma homocysteine levels in healthy human subjects
T2 - A double-blind, placebo-controlled, randomized clinical trial
AU - Thompson, Michael A.
AU - Bauer, Brent A.
AU - Loehrer, Laura L.
AU - Cha, Stephen S.
AU - Mandrekar, Jayawant N.
AU - Sood, Amit
AU - Wahner-Roedler, Dietlind L.
PY - 2009/5/1
Y1 - 2009/5/1
N2 - Objectives: To determine if exogenous S-adenosyl-l-methionine (AdoMet), a commonly used nutritional supplement, increases the level of plasma homocysteine (Hcy), a potential cardiovascular risk factor, in healthy human subjects. Design: Double-blind, placebo-controlled, randomized clinical trial. Setting: Mayo Clinic, Rochester, Minnesota. Subjects: Fifty-two (52) healthy human volunteers. Intervention: Subjects received placebo or AdoMet (800? mg per day) for 4 weeks. Hcy levels were measured before and after administration of AdoMet or placebo. Outcome Measures: The primary outcome measure was change in Hcy level. Secondary outcome measures included an interim Hcy determination (at 2 weeks) and changes in levels of high-sensitivity C-reactive protein (hsCRP), lipids, and alanine aminotransferase. Results: There was no statistically significant change in Hcy between groups. Similarly, no statistically significant differences in change in Hcy or hsCRP levels were observed at 2 or 4 weeks. There was a small but statistically significant increase (p? <? 0.04) in alanine aminotransferase at week 2 and a statistically significant decrease (p? <? 0.04) in total cholesterol in the AdoMet group compared with the placebo group. Conclusions: AdoMet at a daily dose of 800? mg for 4 weeks does not appear to significantly affect Hcy levels in the blood.
AB - Objectives: To determine if exogenous S-adenosyl-l-methionine (AdoMet), a commonly used nutritional supplement, increases the level of plasma homocysteine (Hcy), a potential cardiovascular risk factor, in healthy human subjects. Design: Double-blind, placebo-controlled, randomized clinical trial. Setting: Mayo Clinic, Rochester, Minnesota. Subjects: Fifty-two (52) healthy human volunteers. Intervention: Subjects received placebo or AdoMet (800? mg per day) for 4 weeks. Hcy levels were measured before and after administration of AdoMet or placebo. Outcome Measures: The primary outcome measure was change in Hcy level. Secondary outcome measures included an interim Hcy determination (at 2 weeks) and changes in levels of high-sensitivity C-reactive protein (hsCRP), lipids, and alanine aminotransferase. Results: There was no statistically significant change in Hcy between groups. Similarly, no statistically significant differences in change in Hcy or hsCRP levels were observed at 2 or 4 weeks. There was a small but statistically significant increase (p? <? 0.04) in alanine aminotransferase at week 2 and a statistically significant decrease (p? <? 0.04) in total cholesterol in the AdoMet group compared with the placebo group. Conclusions: AdoMet at a daily dose of 800? mg for 4 weeks does not appear to significantly affect Hcy levels in the blood.
UR - http://www.scopus.com/inward/record.url?scp=67149105905&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67149105905&partnerID=8YFLogxK
U2 - 10.1089/acm.2008.0402
DO - 10.1089/acm.2008.0402
M3 - Article
C2 - 19422296
AN - SCOPUS:67149105905
SN - 1075-5535
VL - 15
SP - 523
EP - 529
JO - Journal of Alternative and Complementary Medicine
JF - Journal of Alternative and Complementary Medicine
IS - 5
ER -